View clinical trials related to Healthy.
Filter by:The purpose of the study is to assess whether high or low arch foot types influence the overall performance of the athlete.
This is an open-label, fixed-sequence, phase 1 study to evaluate the effect of clarithromycin/rifampicin on the pharmacokinetics of DA-8010 in healthy adults.
To determine whether there is an ipsilateral transfer of motor skill from the lower to the upper limb in healthy adults.
The goal of this randomized, counterbalanced, crossover study is to determine the effectiveness of performing a supramaximal walkout on enhancing subsequent back squat performance in trained lifters. The main question we aim to answer is whether bar velocity, power output, perceived exertion, and muscle activation are altered when performing the back squat exercise after a supramaximal walkout. On the first visit, participants will be informed of the study protocols before providing oral and written informed consent. Afterwards, participants will complete maximum voluntary isometric contraction (MVIC) testing for the quadriceps and gluteus maximus muscle groups to generate a normalization for the electromyography (EMG) measurements. During the second visit, participants will perform a 1RM back squat. The third and fourth visits will be the experimental visits, where they will perform either a supramaximal (110% 1RM) or submaximal (control; 30% 1RM) walkout. A set of 1 back squat at 92.5% 1RM will be performed prior to the walkout to serve as a baseline, then 3 sets of 1 at 92.5% 1RM will be performed afterwards.
This study is a Phase Ia, randomized, double-blind, placebo-controlled, single dose, dose escalation safety, tolerability, and pharmacokinetic study of STSA-1201 injection in healthy subjects. A total of 44 healthy subjects were enrolled in four dosage groups.
Resistance exercise may immediately lessen the perception of pain. The purpose of this study is compare the effects of an upper body exercise to a lower body exercise on the perception of pain (pressure pain threshold).
The main purpose of this study is to look if the study drug, tirzepatide, gets into the breast milk and if yes, how long it takes the body to get rid of it. The study drug will be given as a single injection under the skin in healthy lactating females. For each participant, the total duration of the study will be approximately 8 weeks, including screening.
The goal of this clinical study is to establish the comparability of the pharmacokinetics and similarity of the safety, immunogenicity and pharmacodynamic profiles of BCD-264 and Darzalex following a single intravenous infusion in healthy subjects.
The purpose of this study is to evaluate the safety and efficacy of 02 facial sunscreens (investigational products [IPs]) under controlled and normal conditions of use on the face for 28 and 56 days, respectively. This study will consist of 2 groups a) Group 1: will assess the safety and efficacy of a facial sunscreen in improving skin hydration and barrier function, through 12h of single application on the face in comparison with the control area (other side of face) and on the forearm, comparing 02 IPs versus control area (no product application) and 03 benchmarks; and through use of the IP under normal conditions for 28 +/- 2 days on the face, with assessments by instrumental measurements of corneometry, transepidermal water loss, image capture (Colorface) and assessments of the efficacy perceived by the participant; b) Group 2: will evaluate the safety and efficacy of a facial sunscreen in improving skin hydration and barrier function, through 12h of single application on the face; and through use of IP under normal conditions for 28 +/- 2 days on the face, with assessments by instrumental measurements of corneometry, transepidermal water loss, imaging (Colorface) and assessments of the efficacy perceived by the participant; in addition to evaluating the improvement in uniformity of facial skin tone through the use of IP under normal conditions for 56 +/- 2 days, with assessments by image analysis (Colorface), dermatological clinical analyses (radiance and homogeneity of skin tone),assessments of perceived efficacy, and emotional testimony by the participant.
The main objective of this trial is to investigate the effect on the exposure of BI 1815368 in plasma when given as oral single dose together with multiple oral doses of itraconazole (Test, T) as compared to when given alone as oral single dose (Reference, R).